| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Beta-Eudesmol (30-100 μM; 6 days) inhibits the growth of HUVEC cells induced by vascular endothelial growth factor (VEGF) (30 ng/ml) and basic fibroblast growth factor (bFGF) (30 ng/ml). In a time- and dose-dependent manner, Beta-Eudesmol (10-100 μM; 72 hours) inhibits the proliferation of cells in tumors HeLa, SGC-7901, and BEL-7402 [1]. -Eudesmol (10–120 μM; 4 hours) can decrease HL-60 cell viability [4]. In HL-60 cells, beta-eudesmol (40-80 μM; 4 hours) can detect cytochrome c.
|
|---|---|
| ln Vivo |
In MK mice, the intraperitoneal injection of beta-eudesmol (2.5–5 mg/kg; once daily for 7 days) greatly suppresses the growth of tumor cells and new blood vessels [1]. intraperitoneal; 50–100 mg/kg) beta-eudesmol
|
| Cell Assay |
Western Blot Analysis[4]
Cell Types: HL-60 Tested Concentrations: 40 μM, 80 μM Incubation Duration: 4 h Experimental Results: Increased expression of caspase-3 protein. 80 µM. Cell viability assay [4] Cell Types: HL-60 Tested Concentrations: 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, 120 μM Incubation Duration: 4 h Experimental Results: Cell viability was not affected at 40 μM dose, but at 80 μM The cell activity diminished at the dose, and the cell viability diminished by 51.6%. Apoptosis analysis [4] Cell Types: HL-60 Tested Concentrations: 40 μM, 80 μM Incubation Duration: 4 h Experimental Results: 40 μM dose had no effect on cell apoptosis, 80 μM dose induced apoptosis, and the cell apoptosis rate is 31.7%. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6 mouse model [2]
Doses: 50 mg/kg, 100 mg/kg Route of Administration: intraperitoneal (ip) injection; single dose. 2 hrs (hrs (hours)) before cecal ligation and puncture (CLP) surgery. Experimental Results: The expression of TNF-α, IL-1β and IL-6 increased in a dose-dependent manner. Increases levels of superoxide dismutase (SOD) and glutathione (GSH), and decreases levels of malondialdehyde (MDA) and myeloperoxidase (MPO). Inhibits the phosphorylation of p65. |
| References |
[1]. Ma EL,et al. Beta-eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation. J Asian Nat Prod Res. 2008 Jan-Feb;10(1-2):159-67.
[2]. Xu Q, et al. Protective effects of β-eudesmol against septic liver injury via inhibition of NF-κB signaling[J]. Tropical Journal of Pharmaceutical Research, 2022, 21(6): 1183-1188. [3]. Chiou LC, et al. Antagonism by beta-eudesmol of neostigmine-induced neuromuscular failure in mouse diaphragms. Eur J Pharmacol. 1992 Jun 5;216(2):199-206. [4]. Hoang D M, et al. Eudesmols induce apoptosis through release of cytochrome c in HL-60 cells[J]. Natural Product Sciences, 2010, 16(2): 88-92. |
| Molecular Formula |
C15H26O
|
|---|---|
| Molecular Weight |
222.3663
|
| CAS # |
473-15-4
|
| SMILES |
O([H])C(C([H])([H])[H])(C([H])([H])[H])[C@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C(=C([H])[H])[C@]2([H])C1([H])[H]
|
| Synonyms |
Beta-Eudesmol
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~449.70 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (11.24 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4970 mL | 22.4850 mL | 44.9701 mL | |
| 5 mM | 0.8994 mL | 4.4970 mL | 8.9940 mL | |
| 10 mM | 0.4497 mL | 2.2485 mL | 4.4970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
